News | November 07, 2025
AstraZeneca invests additional $136 million to expand Qingdao inhalants facility
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
SmartTrack aims to reduce the need for clinical studies in generic drug product approvals
The company does not expect this development to have any material impact on the current business operations
The Emcure Research Centre (ERC) will drive research across multiple dosage forms, including OSD, injectables, novel drug delivery systems (NDDS), inhalers and topical and transdermal formulations
Lonza to develop spray-dried formulations for an intranasally-delivered biologic for Iconovo at its Center of Excellence for bioavailability enhancement and inhaled delivery in Bend (US)
Afrezza, developed by MannKind Corporation in the USA, offers a needle-free, rapid-acting insulin option for diabetes management
Before joining Gland, Loomba was associated with Shalina Labs, Harman Finochem, Aurobindo Pharma, Sun Pharmaceuticals and Ranabaxy Laboratories.
Subscribe To Our Newsletter & Stay Updated
